Arvinas (ARVN) to Release Earnings on Wednesday

Arvinas (NASDAQ:ARVN) will announce its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, July 30th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.59. The company had revenue of $76.50 million during the quarter, compared to analyst estimates of $33.27 million. Arvinas’s revenue for the quarter was up 40.4% on a year-over-year basis. During the same period in the previous year, the company posted ($1.25) earnings per share. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Trading Down 3.8 %

Shares of NASDAQ ARVN opened at $25.92 on Monday. The firm has a market cap of $1.77 billion, a PE ratio of -4.37 and a beta of 1.97. Arvinas has a 1-year low of $13.57 and a 1-year high of $53.08. The company has a fifty day moving average price of $25.45 and a 200 day moving average price of $27.99.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. Wedbush restated an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research note on Tuesday, July 30th. Barclays reduced their price objective on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Oppenheimer reduced their price objective on shares of Arvinas from $70.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday, July 31st. Finally, HC Wainwright restated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $57.69.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.